Overview

Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The optimal treatment of glioblastoma multiforme (GBM) in patients aged ≥70 years with a Karnofsky performance status (KPS) <70 is unestablished. This clinical trial evaluated the efficacy and safety of upfront temozolomide (TMZ) and bevacizumab (Bev) in patients aged ≥70 years and a KPS <70.

Phase:

Phase 2

Details

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborator:

Roche Pharma AG

Treatments:

Bevacizumab
Dacarbazine
Temozolomide